<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT: AUGUST 7, 2000
(Date of earliest event reported)
THE IMMUNE RESPONSE CORPORATION
(Exact name of registrant as specified in its charter)
DELAWARE 0-18006 33-0255679
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
5935 DARWIN COURT, CARLSBAD, CALIFORNIA 92008
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (760) 431-7080
<PAGE>
Item 7. FINANCIAL STATEMENTS AND EXHIBITS
EXHIBITS
1.1 Underwriting Agreement, dated August 7, 2000 among The
Immune Response Corporation and First Security Van Kasper,
Inc. and Gruntal & Co. LLC.
- 2 -
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: August 8, 2000
THE IMMUNE RESPONSE CORPORATION
By /s/ Howard Sampson
----------------------------
Howard Sampson
Vice President, Finance,
Chief Financial Officer, and Treasurer
- 3 -
<PAGE>
EXHIBIT INDEX
Exhibit Description
------- -----------
1.1 Underwriting Agreement, dated August 7, 2000 among The Immune Response
Corporation and First Security Van Kasper, Inc. and Gruntal & Co. LLC.
- 4 -
